Anagrelide treatment in early pregnancy in a patient with JAK2V617F-positive essential thrombocythemia: case report and literature review.
Sobas
Marta A
MA
Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario, Santiago de Compostela, España. marta.sobas@gmail.com
Pérez Encinas
Manuel M
MM
Rabuñal Martinez
María J
MJ
Quinteiro García
Celsa
C
Bello López
José L
JL
D000328:Adult; D019943:Amino Acid Substitution; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D053614:Janus Kinase 2 / Q000235:genetics*; D017354:Point Mutation; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011799:Quinazolines / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics
D005343:Fibrinolytic Agents; D011799:Quinazolines; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C021139:anagrelide